Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

ENGN - enGene Therapeutics Inc. Последние новости | Finranks

Home

/

ENGN

E

enGene Therapeutics Inc. (ENGN)

NCM – Цена в реальном времени. Валюта: USD

1.44

-0.05 (-3.36%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript

enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript

enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript

enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain

enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain

enGene NASDAQ: ENGN reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ: ENGN). The investigation focuses on enGene's executive officers and whether investor losses may be recovered under federal securities laws.

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) with or without concomitant papillary d.

enGene Announces Name Change to enGene Therapeutics Inc.

enGene Announces Name Change to enGene Therapeutics Inc.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's on.

enGene Holdings: Key Catalysts Incoming For 2026

enGene Holdings: Key Catalysts Incoming For 2026

enGene Holdings remains on track with a cautiously optimistic 'Buy' rating, supported by promising clinical data and strong financial positioning. ENGN's lead candidate, detalimogene voraplasmid, demonstrated a 63% complete response rate at 3 months in NMIBC, with favorable tolerability and pivotal cohort enrollment exceeding targets. ENGN plans a pivotal LEGEND cohort update at a spring 2026 medical conference, with a BLA submission for FDA approval anticipated in the second half of 2026.

enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Видео

No Data

There is no data to display

Пресс-релизы

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ: ENGN). The investigation focuses on enGene's executive officers and whether investor losses may be recovered under federal securities laws.

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) with or without concomitant papillary d.

enGene Announces Name Change to enGene Therapeutics Inc.

enGene Announces Name Change to enGene Therapeutics Inc.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's on.

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update. “As data from LEGEND's pivotal cohort in high-risk, BCG-unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference,” said Ron Cooper, President and Chief Executive Officer, enGe.